Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 87% Improvement Relative Risk Obrișcă et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Prospective study of 95 patients in Romania (Feb 2020 - May 2021) Fewer cases with HCQ (p=0.01) Obrișcă et al., Biomedicines, doi:10.3390/biomedicines10102423 Favors HCQ Favors control
Characteristics of SARS-CoV-2 Infection in an Actively Monitored Cohort of Patients with Lupus Nephritis
Obrișcă et al., Biomedicines, doi:10.3390/biomedicines10102423
Obrișcă et al., Characteristics of SARS-CoV-2 Infection in an Actively Monitored Cohort of Patients with Lupus Nephritis, Biomedicines, doi:10.3390/biomedicines10102423
Sep 2022   Source   PDF  
  All Studies   Meta
Prospective analysis of 95 Lupus Nephritis patients in Romania, showing lower risk of COVID-19 with HCQ use.
risk of case, 86.7% lower, RR 0.13, p = 0.01, treatment 10 of 81 (12.3%), control 5 of 14 (35.7%), NNT 4.3, adjusted per study, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Obrișcă et al., 28 Sep 2022, prospective, Romania, peer-reviewed, mean age 39.0, 12 authors, study period 26 February, 2020 - 1 May, 2021.
Contact: (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: biomedicines Article Characteristics of SARS-CoV-2 Infection in an Actively Monitored Cohort of Patients with Lupus Nephritis Bogdan Obris, că 1,2, *,† , Alexandra Vornicu 1,2,† , Roxana Jurubit, ă 1 , Valentin Mocanu 1 , George Dimofte 1 , Andreea Andronesi 1,2 , Bogdan Sorohan 1,2 , Camelia Achim 1,2 , Georgia Micu 1 , Raluca Bobeică 1 , Constantin Dina 3,† and Gener Ismail 1,2,† 1 2 3 * † Citation: Obris, că, B.; Vornicu, A.; Jurubit, ă, R.; Mocanu, V.; Dimofte, G.; Andronesi, A.; Sorohan, B.; Achim, C.; Micu, G.; Bobeică, R.; et al. Characteristics of SARS-CoV-2 Infection in an Actively Monitored Cohort of Patients with Lupus Nephritis. Biomedicines 2022, 10, 2423. biomedicines10102423 Academic Editor: Cristina Capusa Department of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, Romania Department of Nephrology, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania Department of Anatomy, Ovidius University, 900470 Constant, a, Romania Correspondence: These authors contributed equally to this work. Abstract: (1) Background: We sought to investigate the impact of the COVID-19 pandemic in patients with lupus nephritis (LN); (2) Methods: A total of 95 patients with LN actively monitored in our department between 26 February 2020, when the first case of COVID-19 was diagnosed in Romania, and 1 May 2021, were included in the study. Multivariate logistic regression analysis was performed to identify the independent risk factors for SARS-CoV-2 infection; (3) Results: A total of 15 patients (15.8%) had a confirmed SARS-CoV-2 infection during a total follow-up time of 105.9 patient-years (unadjusted incidence rate: 14.28 SARS-CoV-2 infections per 100 patient-years). Median time to SARS-CoV-2 infection was 9.3 months (IQR: 7.2–11.3). The majority of patients had a mild form of SARS-CoV-2 infection (73.3%), while the remaining had moderate forms. None of the patients had a severe infection or a SARS-CoV-2-related death. The most frequent symptom was fatigue (73.3%), followed by loss of taste/smell (53.3%) and fever (46.7%). Forty percent of those with SARSCoV-2 infection were hospitalized for a median 11.5 days (IQR:3.75–14). In the multivariate logistic regression analysis, a current oral corticosteroid dose ≥ 15 mg/day was associated with a 7.69-fold higher risk (OR, 7.69; 95%, 1.3–45.46), while the use of hydroxychloroquine was associated with a 91% lower risk for a SARS-CoV-2 infection (OR, 0.09; 95%CI, 0.01–0.59). (4) Conclusions: Our study confirms that the SARS-CoV-2 infection-associated morbidity might only be moderately increased in patients with LN. The current oral corticosteroid dose was the only independent predictor of infection occurrence, while use of hydroxychloroquine was associated with a protective effect. Keywords: lupus nephritis; SARS-CoV-2 infection; corticosteroids; hydroxychloroquine Received: 27 August 2022 Accepted: 24 September 2022 Published: 28 September 2022 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// 4.0/).
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop